الصفحة الرئيسية>>Lipids>> P450>>Tetrahydropiperine

Tetrahydropiperine (Synonyms: THP)

رقم الكتالوجGC40258

Tetrahydropiperine ، وهو نظير سيكلوهكسيل للبيبيرين ، هو أول أريل خماسي طبيعي طبيعي من بايبر لونغوم. Tetrahydropiperine (المركب 14) يثبط السيتوكروم P450 (CYP) isoform CYP1A1 / arylhydrocarbon hydroxylase (AHH ؛ IC50 = 23 μ ؛ M).

Products are for research use only. Not for human use. We do not sell to patients.

Tetrahydropiperine التركيب الكيميائي

Cas No.: 23434-88-0

الحجم السعر المخزون الكميّة
1mg
42٫00
متوفر
5mg
188٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tetrahydropiperine is a derivative of piperine and an arylpentanamide originally isolated from P. longum that has diverse biological activities. It is an agonist of transient receptor potential vanilloid type 1 (TRPV1; EC50 = 6.3 µM). It inhibits the cytochrome P450 (CYP) isoform CYP1A1/arylhydrocarbon hydroxylase (AHH; IC50 = 23 µM) and 7-methoxycoumarin O-demethylase (MOCD) activity (IC50 = 25 µM) in rat liver microsomes. Tetrahydropiperine increases skin pigmentation in a mouse model of vitiligo when 100 µl of a 175 mM solution is administered topically, an effect that can be enhanced by subsequent suberythemal ultraviolet radiation (UVR). Formulations containing tetrahydropiperine have been used to increase bioavailability of compounds applied to the skin.

مراجعات

Review for Tetrahydropiperine

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tetrahydropiperine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.